 Aclaris Therapeutics, Inc. CICN, a physician-led biopharmaceutical company, today announced that it has entered into a loan and security agreement with Silicon Valley Bank SVB pursuant to which Aclaris has borrowed 11.0 million. Aclaris believes the proceeds from the loan, in combination with its existing cash, cash equivalents, and marketable securities, will be sufficient to fund its operations into the first quarter of 2022. The term loan requires interest only payments beginning April 1, 2020 and continuing through March 1, 2022, followed by monthly installments of principal, plus monthly payments of accrued interest, starting on April 1, 2022 and continuing through March 1, 2024. 